Eli Lilly has launched Foundayo™ (orforglipron), an oral GLP-1 receptor agonist approved by the FDA for weight management in adults with obesity or overweight conditions linked to medical issues. This medication is notable for its once-daily dosing that allows flexibility with food and water intake, making it a convenient option for patients. Priced at $25 per month with commercial insurance and $149 for self-pay patients, Foundayo is now accessible via LillyDirect® and telemedicine providers, with distribution expanding to retail pharmacies across the U.S.

The clinical significance of Foundayo is underscored by data from the ATTAIN clinical trial program, where participants on the highest dose lost an average of 27.3 pounds (12.4%) compared to 2.2 pounds (0.9%) in the placebo group over 72 weeks. Additionally, the treatment led to reductions in cardiovascular risk markers, including waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure. These findings suggest that Foundayo not only aids in weight loss but also may improve metabolic health, offering a dual benefit that could enhance patient outcomes.

The introduction of Foundayo could shift the landscape of obesity treatment by providing a novel oral option that complements existing therapies. Its availability may accelerate research into the long-term effects of GLP-1 receptor agonists on healthspan and longevity, particularly as it is also being investigated for conditions like Type 2 diabetes and hypertension. This advancement highlights the ongoing need for effective obesity management solutions, particularly in a healthcare environment where coverage for such treatments is often inconsistent.

Source: investor.lilly.com